Dr. Socinski on Recent Setbacks in Immunotherapy Combinations in NSCLC – OncLive
OncLive |
Dr. Socinski on Recent Setbacks in Immunotherapy Combinations in NSCLC
OncLive Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses recent setbacks in immunotherapy combinations in non–small cell lung cancer (NSCLC). In January 2017, both Bristol-Myers Squibb (BMS) an AstraZeneca … |
